Significance of Neuroleptic Dose and Plasma Level in the Pharmacological Treatment of Psychoses

Archives of General Psychiatry

Volumn 45, Issue 1, 1988, Pages 79-91

  Baldessarini, Ross J ^a,b   Cohen, Bruce M ^a,b   Teicher, Martin H ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; BLOOD LEVEL; CLINICAL ARTICLE; HUMAN; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; PSYCHOSIS;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMAN; PSYCHOTIC DISORDERS; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0023873890     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1988.01800250095013     Document Type: Article

References (200)

1. Baldessarini RJ: Antipsychotic agents, in Karasu B (ed): Psychiatric Therapies. Washington, DC, American Psychiatric Association, 1984, pp 119-170.
2. Baldessarini RJ: Chemotherapy in Psychiatry: Principles and Practice. Cambridge, Mass, Harvard University Press, 1985.
3. Cohen BM, Lipinski JF: The treatment of acute psychosis with nonneuroleptic agents. Psychosomatics 1986;27:7-16.
4. Baldessarini RJ, Cole JO, Davis JM, Gardos G, Simpson G, Tarsy D: Tardive Dyskinesia: Task Force Report 18. Washington, DC, American Psychiatric Association, 1980.
5. Appleton WS, Davis JM: Practical Clinical Psychopharmacology, ed 2. Baltimore, Williams & Wilkins, 1980.
6. Baldessarini RJ, Katz B, Cotton P: Dissimilar dosing with highpotency and low-potency neuroleptics. Am J Psychiatry 1984;141:748-752.
7. Kane JM, Rifkin A, Woerner M, Reardon G, Sarantoakis S, Schiebel D, Ramos-Lorenzi J: Low-dose neuroleptic treatment of outpatient schizophrenics. Arch Gen Psychiatry 1983;40:893-896.
8. Lehmann H, Wilson WH, Deutsch M: Minimal maintenance medication: Effects of three dose schedules on relapse rates and symptoms in chronic schizophrenic outpatients. Compr Psychiatry 1983;24:293-303.
9. Ayd FJ Jr: Large doses of chlorpromazine in the treatment of psychiatric patients. Dis Nerv Syst 1955;16:146-149.
10. Wilkens B, Malitz S: Some problems of dose variations in the use of tranquilizing drugs. Am J Psychiatry 1960;117:23-29.
11. Gardos G, Cole JO, Orzack MH: The importance of dosage in antipsychotic drug administration: A review of dose-response studies. Psychopharmacologia 1973;29:221-230.
12. Gardos G, Cole JO: Maintenance antipsychotic therapy: Is the cure worse than the disease? Am J Psychiatry 1976;133:32-36.
13. Donlon PT: High dosage neuroleptic therapy. Int Pharmacopsychiatry 1976;11:235-245.
14. Donlon PT, Hopkin J, Tupin JP: Overview: Efficacy and safety of the rapid neuroleptization method with injectable haloperidol. Am J Psychiatry 1979;136:273-278.
15. Woggon B: Neuroleptika-Absetzverstudie bei chronisch schizophrenen Patienten: I. Literaturzusammenfassung. Int Pharmacopsychiatry 1979;14:34-56.
16. Aubree JC, Lader MH: High and very high dosage antipsychotics: A critical review. J Clin Psychiatry 1980;41:341-350.
17. Mason AS, Granacher RP: Rapid tranquilization methods, in Clinical Handbook of Antipsychotic Drug Therapy. New York, Brunner/Mazel Inc, 1980, pp 109-141.
18. Cole JO: Antipsychotic drugs: Is more better? McLean Hosp J 1982;7:61-87.
19. Kirkpatrick B, Burnett GB: Observations on neuroleptic use in acutely psychotic patients. J Clin Psychopharmacol 1982;2:205-207.
20. Linden R, Davis JM, Rubenstein J: High vs. low dose treatment with antipsychotic agents. Psychiatr Ann 1982;12:769-781.
21. Kinross-Wright J: The intensive chlorpromazine treatment of schizophrenia. Psychiatry Res Rep 1955;1:53-62.
22. Danik JJ, Goverdham M: Haloperidol in the treatment of 120 psychotic patients. Am J Psychiatry 1963;12:389-391.
23. Mountain HE: Crash tranquilization in a milieu therapy setting. J Fort Logan Health Center 1963;1:43-44.
24. Oldham AJ, Bott M: The management of excitement in a general hospital psychiatric ward by high dosage haloperidol. Acta Psychiatr Scand 1971;47:369-376.
25. Polack P, Laycob L: Rapid tranquilization. Am J Psychiatry 1971;128:640-643.
26. Sangiovanni F, Taylor MA, Abrams R, Gaztanaga P: Rapid control of psychotic excitement states with intramuscular haloperidol. Am J Psychiatry 1973;130:1155-1156.
27. Donlon PT, Tupin JP: Rapid ‘digitalization’ of decompensated schizophrenic patients with antipsychotic agents. Am J Psychiatry 1974;131:310-312.
28. Carter RG: Psychotolysis with haloperidol: Rapid control of the acutely disturbed psychotic patient. Dis Nerv Syst 1977;38:237-239.
29. Carter RG: Use of oral haloperidol following rapid tranquilization of acutely disturbed patients. W Va Med J 1978;74:55-56.
30. Firling RJ: Acutely disturbed psychotic patients treated with parenteral haloperidol. Int Med J 1978;117:153-154.
31. Zarifian E, Scatton B, Bianchetti G, Cuche H, Loo H, Morselli PL: High doses of haloperidol in schizophrenia: A clinical biochemical and pharmacokinetic study. Arch Gen Psychiatry 1982;39:212-215.
32. Bollini P, Andreain A, Colombo F, Bellantuono C, Beretta P, Ardiori A, Galli T, Togononi G: High dose neuroleptics: Uncontrolled clinical practice confirms controlled clinical trials. Br J Psychiatry 1984;144:25-27.
33. Fitzgerald CH: A double-blind comparison of haloperidol with perphenazine in acute psychotic episodes. Curr Ther Res 1969;11:515-519.
34. Slotnick VVB: Management of the acutely agitated psychotic patient with parenteral neuroleptics: A comparative symptom effectiveness profile of haloperidol and chlorpromazine. Read before the Fifth World Congress of Psychiatry, Mexico City, Nov 15, 1971.
35. Ritter RM, Davidson DE, Robinson TA: Comparison of injectable haloperidol and chlorpromazine. Am J Psychiatry 1972;129:78-81.
36. Chien C-P, Cole JO: Depot phenothiazine treatment in acute psychosis: A sequential comparative clinical study. Am J Psychiatry 1973;130:13-17.
37. Man PL, Chen CH: Rapid tranquilization of acutely psychotic patients with intramuscular haloperidol and chlorpromazine. Psychosomatics 1973;14:59-63.
38. Reschke RW: Parenteral haloperidol for rapid control of severe, disruptive symptoms of acute schizophrenia. Dis Nerv Syst 1974;35:112-115.
39. Wijsenbeek H, Steiner M, Goldberg SC: Trifluoperazine: A comparison between regular and high doses. Psychopharmacologia 1974;36:147-150.
40. Quitkin F, Rifkin A, Kaplan JH, Klein DF: Treatment of acute schizophrenia with ultra-high-dose fluphenazine: A failure at shortening time on a crisis-intervention unit. Compr Psychiatry 1975;16:279-283.
41. Anderson WH, Kuehnle JC, Catanzano DM: Rapid treatment of acute psychosis. Am J Psychiatry 1976;133:1076-1078.
42. Levenson AJ, Burnett GB, Nottingham JD, Sermas CE, Thornby JI: Speed and rate of remission in acute schizophrenia: A comparison of intramuscularly administered fluphenazine HCI with thiothixene and haloperidol. Curr Ther Res 1976;20:695-700.
43. Gerstenzang ML, Krulisky TV: Parenteral haloperidol in psychiatric emergencies: Double-blind comparison with chlorpromazine. Dis Nerv Syst 1977;38:581-583.
44. Paprock J, Versiani M: A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia. Curr Ther Res 1977;21:80-100.
45. Stotsky BA: Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients. Dis Nerv Syst 1977;38:967-973.
46. Donlon PT, Meadow A, Tupin JP, Wahba M: High vs. standard dosage fluphenazine HCI in acute schizophrenia. J Clin Psychiatry 1978;39:800-804.
47. Erickson SE, Hurt SW, Chang S: Haloperidol dose, plasma levels, and clinical response: A double blind study. Psychopharmacol Bull 1978;14:15-16.
48. Donlon PT, Hokin JT, Tupin JP: Haloperidol for acute schizophrenic patients: An evaluation of three oral regimens. Arch Gen Psychiatry 1980;37:691-695.
49. Neborsky R, Janowsky D, Munson E, Depry D: Rapid treatment of acute psychiatric symptoms with high- and low-dose haloperidol. Arch Gen Psychiatry 1981;38:195-199.
50. Escobar JI, Barron A, Kiriakos R: A controlled study of ‘neuroleptization’ with fluphenazine hydrochloride injections. J Clin Psychopharmacol 1983;3:359-362.
51. Dubin WR, Waxman HM, Weiss KJ, Ramchandani D, Tavani-Tetrone C: Rapid tranquilization: The efficacy of oral concentrate. J Clin Psychiatry 1985;46:475-478.
52. Lerner Y, Lwow E, Levitan A, Belmaker RH: Acute high-dose parenteral haloperidol treatment of psychosis. Am J Psychiatry 1979;136:1061-1064.
53. Guz I, Moraes R, Sartoretto JN: The therapeutic effects of lorazepam in psychotic patients treated with haloperidol: A double-blind study. Curr Ther Res 1972;14:767-774.
54. Koster van Groos GA: The treatment of neurotic and psychotic anxiety with lorazepam. Curr Med Res Opin 1973;1:288-290.
55. Deberdt R: Lorazepam in the treatment of severe anxiety and anxiety associated with psychotic conditions. Curr Med Res Opin 1973;1:296-300.
56. Shader RI, Elkins R, Ciraulo D: On guidelines for maximum dosages. Am J Psychiatry 1977;135:499-500.
57. Beckmann H, Haas S: High dose diazepam in schizophrenia. Psychopharmacology 1980;71:79-82.
58. Chouinard G, Young SN, Annable L: Antimanic effect of clonazepam. Biol Psychiatry 1983;18:451-466.
59. Victor BS, Link NA, Binder RL, Bell IR: Use of clonazepam in mania and schizoaffective disorders. Am J Psychiatry 1984;141:1111-1112.
60. Frykholm B: Clonazepam: Antipsychotic effect in a case of schizophrenia-like psychosis with epilepsy and in three cases of atypical psychosis. Acta Psychiatr Scand 1985;71:539-542.
61. Modell JG, Lenox RH, Weiner S: Inpatient clinical trial of lorazepam for the management of manic agitation. J Clin Psychopharmacol 1985;5:109-113.
62. Simpson GM, Varega E, Haber EJ: Psychotic exacerbations produced by neuroleptics. Dis Nerv Syst 1976;37:367-369.
63. Marder SR, Van Putten T, Mintz J, McKenzie J, Lobell M, Faltico G, May PRA: Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 1984;41:1025-1029.
64. Diamond R: Drugs and the quality of life: The patient's point of view. J Clin Psychiatry 1985;46:29-35.
65. Teicher MH, Baldessarini RJ: Selection of neuroleptic dosage. Arch Gen Psychiatry 1985;42:636-637.
66. Keepers GA, Clappison VJ, Casey DE: Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry 1983;40:1113-1117.
67. Task Force on the Use of Laboratory Tests in Psychiatry: Tricyclic antidepressants: Blood level measurements and clinical outcome: An APA Task Force report. Am J Psychiatry 1985;142:155-162.
68. Cooper TB, Simpson GM: The 24-hour lithium-level as a prognosticator of dosage requirements: A two-year follow-up study. Am J Psychiatry 1976;133:440-443.
69. Cooper TB, Simpson GM: Prediction of individual dosage of nortriptyline. Am J Psychiatry 1978;135:333-335.
70. Brunswick DJ, Amsterdam JD, Mendels J, Stern SL: Prediction of steady-state imipramine and desmethylimipramine plasma concentrations from single-dose data. Clin Pharmacol Ther 1979;25:605-610.
71. Curry SH: Determination of nanogram quantities of chlorpromazine and some of its metabolites in plasma using gas-liquid chromatography with an electron capture detector. Anal Chem 1968;40:1251-1255.
72. Curry SH: The strategy and value of neuroleptic drug monitoring. J Clin Psychopharmacol 1985;5:263-271.
73. Cohen BM: The clinical utility of plasma neuroleptic levels, in Stancer HC, Garfinkel PE, Rakoff VM (eds): Guidelines for the Use of Psychotropic Drugs. Jamaica, NY, Spectrum Publications Inc, 1983, pp 246-260.
74. Cohen BM, Baldessarini RJ: Blood neuroleptic levels as a guide to clinical treatment, in Flach FF (ed): Directions in Psychiatry. New York, Hatherleigh Co Ltd, 1984, vol 4, part 37, pp 1-7.
75. Creese I, Snyder SH: A novel, simple and sensitive radioreceptor assay for antischizophrenic drugs in blood. Nature 1977;270:180-182.
76. Cohen BM, Herschel M, Aoba A: Neuroleptic, antimuscarinic, and antiadrenergic activity of chlorpromazine, thioridazine, and their metabolites. Psychiatry Res 1979;1:199-208.
77. Cohen BM, Lipinski JF, Harris PQ, Pope HG Jr, Friedman M: Clinical use of the radioreceptor assay for neuroleptics. Psychiatry Res 1980;2:173-178.
78. Cohen BM, Lipinski JF, Pope HG, Harris PQ, Altesman RI: Neuroleptic blood levels of patients on thioridazine and clinical improvement. Psychopharmacology 1980;70:191-194.
79. Cooper TB: Neuroleptic drug monitoring and radioreceptor assays. J Clin Psychopharmacol 1985;5:A15-A16.
80. Cooper TB, Simpson GM, Lee HJ: Thymoleptic and neuroleptic drug plasma levels in psychiatry: Current status. Int Rev Neurobiol 1976;19:269-309.
81. Davis JM, Erickson SE, Dekirmenjian H: Plasma levels of antipsychotic drugs and clinical response, in Lipton MA, DiMascio A, Killam KF (eds): Psychopharmacology: A Generation of Progress. New York, Raven Press, 1978, pp 905-916.
82. May PRA, Van Putten T: Plasma levels of chlorpromazine in schizophrenia: A critical review of the literature. Arch Gen Psychiatry 1978;35:1081-1087.
83. Gelder M, Kolakowska T: Variability of response to neuroleptics in schizophrenia. Compr Psychiatry 1979;20:397-408.
84. Cohen BM, Lipinski JF: Radioreceptor assays of blood levels of neuroleptics, in Usdin E (ed): Neuroreceptors: Basic and Clinical Aspects. New York, John Wiley & Sons Inc, 1981, pp 199-214.
85. Ko GN, Korpi ER, Linnoila M: On the clinical relevance and methods of quantification of plasma concentrations of neuroleptics. J Clin Psychopharmacol 1985;5:253-262.
86. McIntyre IM, Gershon S: Interpatient variations in antipsychotic therapy. J Clin Psychiatry 1985;46:3-5.
87. Simpson GM, Yadalam K: Blood levels of neuroleptics: The state of the art. J Clin Psychiatry 1985;46:22-28.
88. Gottschalk LA: A preliminary approach to the problems of relating the pharmacokinetics of phenothiazines to clinical response with schizophrenic patients, in Gottschalk LA (ed): Pharmacokinetics of Psychoactive Drugs, Further Study. Jamaica, NY, Spectrum Publications Inc, 1979, pp 63-81.
89. Cohen BM, Herschel M, Miller EM, Mayberg H, Baldessarini RJ: Radioreceptor assay of haloperidol tissue levels in the rat. Neuropharmacology 1980;19:663-668.
90. Janssen PAJ, Allewijn FTN: The distribution of the butyrophenones haloperidol, trifluperidol, moperone, and clofluperol in rats, and its relationship with their neuroleptic activity. Drug Res 1969;19:199-208.
91. Ohman R, Larsson M, Nilsson IM: Neurometabolic and behavioural effects of haloperidol in relation to drug level in serum and brain. Naunyn Schmiedebergs Arch Pharmacol 1977;299:105-114.
92. Campbell A, Herschel M, Cohen BM, Baldessarini RJ: Tissue levels of haloperidol by radioreceptor assay and behavioral effects of haloperidol in the rat. Life Sci 1980;27:633-640.
93. Neimegeers CJE, Heykauts JJP, Janssen PAJ: Antiemetic effect of haloperidol in the dog as related to plasma level and dose. Psychopharmacology 1981;75:240-244.
94. Campbell A, Herschel M, Madsen JR, Sommer B, Cohen BM, Baldessarini RJ: Circadian changes in the distribution and effects of haloperidol in the rat. Neuropharmacology 1982;21:663-669.
95. May PRA, Van Putten T, Jenden DJ, Yale C, Dixon WV: Chlorpromazine levels and the outcome of treatment in schizophrenic patients. Arch Gen Psychiatry 1981;38:202-207.
96. Yesavage JA, Holman CA, Cohn R, Combrato L: Correlation of initial thiothixene serum levels and clinical response. Arch Gen Psychiatry 1983;40:301-304.
97. Curry SH, Marshall JHL, Davis JM, Janowsky DA: Chlorpromazine plasma levels and effects. Arch Gen Psychiatry 1970;22:289-296.
98. Smith RC, Crayton J, Dekirmenjian H, Klass D, Davis JM: Blood levels of neuroleptic drugs in nonresponding chronic schizophrenic patients. Arch Gen Psychiatry 1979;36:579-584.
99. Brown WA, Silver MA: Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate. J Clin Psychopharmacol 1985;5:143-147.
100. Baldessarini RJ, Cohen BM, Teicher MH: Pharmacological treatment of psychoses with neuroleptic agents, in Levy ST, Ninan PT (eds): Treatment of Acute Psychosis: Current Concepts and Controversies. New York, Jason Aronson Inc, in press.
101. Lader M: Monitoring plasma concentrations of neuroleptics. Pharmakopsychiatrie 1976;9:170-177.
102. Vanderheeren FAJ, Muusze RG: Plasma levels and half-lives of thioridazine and some of its metabolites. Eur J Clin Pharmacol 1977;11:135-140.
103. Clark ML, Kaul PN, Whitfield CR: Chlorpromazine kinetics and clinical response. Psychopharmacol Bull 1978;14:43-45.
104. Wode-Helgodt B, Borg S, Fryo B, Sedvall G: Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine. Acta Psychiatr Scand 1978;58:149-173.
105. Casper R, Garver DL, Dekirmenjian H, Chang S, Davis JM: Phenothiazine levels in plasma and red blood cells. Arch Gen Psychiatry 1980;37:301-305.
106. Dysken MW, Javaid JI, Chang SS, Schaffer C, Shahid A, Davis JM: Fluphenazine pharmacokinetics and therapeutic response. Psychopharmacology 1981;73:205-210.
107. Hansen CB, Larsen N-E, Gulmann N: Dose-response relationship of perphenazine in the treatment of acute psychoses. Psychopharmacology 1982;27:112-115.
108. Greenberg JS, Brown WA, Laughren TP, Krantz J: Neuroleptic levels by radioreceptor assay and clinical response during treatment of acute exacerbations of schizophrenia: Some preliminary findings. Psychopharmacol Bull 1983;19:74-75.
109. Van Putten T, May PRA, Marder SR, Wilkins JN, Rosenberg BJ: Plasma levels of thiothixene by radioreceptor assay: Clinical usefulness. Psychopharmacology 1983;79:40-44.
110. Garver DL, Hirschowitz J, Glicksteen GA, Kanter DR, Mavroidis ML: Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J Clin Psychopharmacol 1984;4:133-137.
111. Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL: Clinical relevance of thiothixene plasma levels. J Clin Psychopharmacol 1984;4:155-157.
112. Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL: Therapeutic blood levels of fluphenazine: Plasma or RBC determinations? Psychopharmacol Bull 1984;20:168-170.
113. Bigelow LB, Kirch DG, Braun T, Korpi ER, Wagner RL, Zalcman S, Wyatt RJ: Absence of a relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: A fixed-dose study. Psychopharmacol Bull 1985;21:66-68.
114. Davis JM, Erickson SE, Hurt S, Chang SS, Javaid JI, Dekirmenjian H, Casper R: Haloperidol plasma levels and clinical response: Basic concepts and clinical data. Psychopharmacol Bull 1985;21:48-51.
115. Potkin SG, Shen Y, Zhou D, Pardes H, Shu L, Phelps B, Poland R: Does a therapeutic window for plasma haloperidol exist? Preliminary Chinese data. Psychopharmacol Bull 1985;21:59-61.
116. Smith RC, Baumgartner R, Burd A, Ravichandran GK, Mauldin M: Haloperidol and thioridazine drug levels and clinical response in schizophrenia: Comparison of gas-liquid chromatography and radioreceptor drug level assay. Psychopharmacol Bull 1985;21:52-58.
117. Smith RC, Baumgartner R, Shvartsburd A, Ravichandran GK, Vroulis G, Mauldin M: Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia. Psychopharmacology 1985;85:449-455.
118. Van Putten T, Marder SR, May PRA, Poland RE, O'Brien RP: Plasma levels of haloperidol and clinical response. Psychopharmacol Bull 1985;21:69-72.
119. Smith RC, Vroulis G, Shvartsburd A, Allen R, Lewis N, Schooler JC, Chojnacki M, Johnson R: RBC and plasma levels of haloperidol and clinical response in schizophrenia. Am J Psychiatry 1982;139:1054-1056.
120. Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL: Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology 1983;81:354-356.
121. Bishop MP, Gallant DM, Sykes TF: Extrapyramidal side effects and therapeutic response. Arch Gen Psychiatry 1965;13:155-162.
122. May PRA, Van Putten T: Plasma levels of chlorpromazine in schizophrenia. Arch Gen Psychiatry 1978;35:1081-1087.
123. Baldessarini RJ, Davis JM: What is the best maintenance dose of neuroleptics in schizophrenia? Psychiatry Res 1980;3:115-122.
124. Shawver J, Gorham DR, Leskin LW, Good WW, Kabnick DE: Comparison of chlorpromazine and reserpine in maintenance drug therapy. Dis Nerv Syst 1959;20:452-457.
125. Tuteur W, Stiller R, Glotzer J: The discharged mental hospital chlorpromazine patient. Dis Nerv Syst 1959;20:512-517.
126. Diamond LS, Marks JB: Discontinuance of tranquilizers among chronic schizophrenic patients receiving maintenance dosage. J Nerv Ment Dis 1960;131:247-251.
127. Engelhardt DM, Freedman N, Glick BS, Hankoff LD, Mann D, Margolis R: Prevention of psychiatric hospitalization with the use of psychopharmacological agents. JAMA 1960;173:147-149.
128. Gross M: The impact of ataractic drugs on a mental hospital outpatient clinic. Am J Psychiatry 1960;117:444-448.
129. Blackburn HL, Allen JL: Behavioral effects in interrupting and resuming tranquilizing medication among schizophrenics. J Nerv Ment Dis 1961;133:303-308.
130. Schiele BC, Vestre ND, Stein KE: A comparison of thioridazine, trifluoperazine, chlorpromazine, and placebo: A double-blind controlled study on the treatment of chronic hospitalized, schizophrenic patients. J Clin Exp Psychopathol 1961;22:151-162.
131. Freeman LS, Alson E: Prolonged withdrawal of chlorpromazine in chronic patients. Dis Nerv Syst 1962;23:522-525.
132. Troshinsky CH, Aaronson HG, Stone RK: Maintenance phenothiazines in aftercare of schizophrenic patients. Penn Psychiatr Q 1962;2:11-15.
133. Whitaker CB, Hoy RM: Withdrawal of perphenazine in chronic schizophrenia. Br J Psychiatry 1963;109:422-427.
134. Caffey EM, Diamond LS, Frank TV, Grasberger JC, Herman L, Klett CJ, Rothstein C: Discontinuation or reduction of chemotherapy in chronic schizophrenics. J Chronic Dis 1964;17:347-358.
135. Pasamanick B, Scarpitti FR, Lefton M, Dinitz S, Wernet JJ, McPheeters H: Home vs. hospital care for schizophrenics. JAMA 1964;187:177-181.
136. Kinross-Wright J, Charalampous KD: A controlled study of a very long-acting phenothiazine preparation. Int J Neuropsychiatry 1965;1:66-70.
137. Garfield SL, Gershon S, Sletten I, Neubauer H, Ferrel E: Withdrawal of ataractic medication in schizophrenic patients. Dis Nerv Syst 1966;27:321-325.
138. Melnyk WT, Worthington AG, Laverty SG: Abrupt withdrawal of chlorpromazine and thioridazine from schizophrenic inpatients. Can Psychiatr Assoc J 1966;11:410-413.
139. Englehardt DM, Rosen B, Freedman N, Margolis R: Phenothiazines in prevention of psychiatric hospitalization. Arch Gen Psychiatry 1967;16:98-101.
140. Prien RF, Cole JO: High dose chlorpromazine therapy in chronic schizophrenia. Arch Gen Psychiatry 1968;18:482-495.
141. Prien RF, Cole JO, Belkin NF: Relapse in chronic schizophrenics following abrupt withdrawal of tranquilizing drugs. Br J Psychiatry 1969;115:679-686.
142. Prien RF, Levine J, Cole JO: High dose trifluoperazine therapy in chronic schizophrenia. Am J Psychiatry 1969;126:305-313.
143. Itil T, Keskiner A: Fluphenazine hydrochloride, enanthate, and decanoate in the management of chronic psychosis. Dis Nerv Syst 1970;31 (suppl):37-42.
144. Leff JP, Wing JK: Trial of maintenance therapy in schizophrenics. Br Med J 1971;3:599-604.
145. Hershon HI, Kennedy PF, McGuire RJ: Persistence of extrapyramidal disorders and psychiatric relapse after withdrawal of long-term phenothiazine therapy. Br J Psychiatry 1972;120:41-50.
146. Hirsch SR, Gaind R, Rohde PD, Stevens BC, Wing JK: Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: Double-blind placebo trial. Br Med J 1973;1:633-637.
147. Hogarty GE, Goldberg SC, Collaborative Study Group: Drugs and sociotherapy in the aftercare of schizophrenic patients: One-year relapse rates. Arch Gen Psychiatry 1973;30:54-64.
148. Hogarty GE, Goldberg SC, Schooler NR, Ulrich RF: Drugs and sociotherapy in the aftercare of schizophrenic patients: II. Two-year relapse rates. Arch Gen Psychiatry 1974;31:603-608.
149. Hogarty GE, Ulrich RF, Mussare F, Aristigueta N: Drug discontinuation among long-term successfully maintained schizophrenic outpatients. Dis Nerv Syst 1976;37:494-500.
150. Hogarty GE, Ulrich RF: Temporal effects of drug and placebo in delaying relapse in schizophrenic outpatients. Arch Gen Psychiatry 1977;34:297-301.
151. Hogarty GE, Schooler NR, Ulrich RF, Mussare F, Ferro P, Herron E: Fluphenazine and social therapy in the aftercare of schizophrenic patients. Arch Gen Psychiatry 1979;36:1283-1294.
152. Gross HL: A double-blind comparison of once-a-day pimozide, trifluoperazine and placebo in the maintenance care of chronic schizophrenic outpatients. Curr Ther Res 1974;16:696-705.
153. Chien C-P: Drugs and rehabilitation in schizophrenia, in Greenblatt M (ed): Drugs in Combination With Other Therapies. New York, Grune & Stratton, 1975, pp 13-34.
154. Clark ML, Huber W, Hill D, Wood F, Costiloe JP: Pimozide (and thioridazine) in chronic outpatients. Dis Nerv Syst 1975;36:137-141.
155. Andrews P, Hall JN, Snaith RP: A controlled trial of phenothiazine withdrawal in chronic schizophrenic patients. Br J Psychiatry 1976;128:451-455.
156. Johnson DAW: The duration of maintenance therapy in chronic schizophrenia. Acta Psychiatr Scand 1976;53:298-301.
157. Rifkin A, Quitkin F, Robiner DJ, Klein DF: Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics: I. Relapse rates after one year. Arch Gen Psychiatry 1977;34:43-47.
158. Quitkin F, Rifkin A, Kane J, Ramos-Lorenzi JR, Klein DF: Longacting oral vs. injectable antipsychotic drugs in schizophrenics: A one-year double-blind comparison in multiple episode schizophrenics. Arch Gen Psychiatry 1978;35:889-892.
159. Levine J, Schooler NR, Severe J, Escobar J, Gelenberg A, Mandel M, Sovner R, Steinbook R: Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: A controlled study. Adv Biochem Psychopharmacol 1980;24:483-493.
160. Muller P, Kind J: A study on the prophylaxis of relapse. Reported by Hartmann W, Kind J, Meyer JE, Muller P, Steuber H: Neuroleptic drugs and the prevention of relapse in schizophrenia: A workshop report. Schizophr Bull 1980;6:536-541.
161. Branchey MH, Branchey LB, Richardson MA: Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients. Am J Psychiatry 1981;138:608-612.
162. Cheung HK: Schizophrenics fully remitted on neuroleptics for threefive years: To stop or continue drugs? Br J Psychiatry 1981;138:490-494.
163. Wistedt B: A depot neuroleptic withdrawal study: A controlled study of the clinical effects of the withdrawal of depot fluphenazine decanoate and depot flupenthixol decanoate in chronic schizophrenic patients. Acta Psychiatr Scand 1981;64:65-84.
164. Kane JM, Rifkin A, Quitkin F, Nayak D, Ramos-Lorenzi J: Fluphenazine vs. placebo in patients with remitted, acute first-episode schizophrenia. Arch Gen Psychiatry 1982;39:70-73.
165. Johnson DAW, Pasterski G, Ludlow JM, Street K, Taylor RDW: The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: Drug and social consequences. Acta Psychiatr Scand 1983;67:339-352.
166. Nishikawa T, Tsuda A, Tanaka M, Koga I, Uchida Y: Prophylactic effects of neuroleptics in symptom-free schizophrenics: Roles of dopaminergic and noradrenergic blockers. Biol Psychiatry 1985;20:1161-1166.
167. Chouinard G, Jones BB, Annable L: Neuroleptic-induced supersensitivity psychosis. Am J Psychiatry 1978;135:1409-1410.
168. Gurland BJ, Fleiss JL, Cooper JE, Sharpe L, Kendall RE, Roberts P: Cross-national study of diagnosis of mental disorders: Hospital diagnoses and hospital patients in New York and London. Compr Psychiatry 1970;11:18-25.
169. Kane JM, Smith JM: Tardive dyskinesia: Prevalence and risk factors, 1959 to 1979. Arch Gen Psychiatry 1982;39:473-481.
170. Quitkin F, Rifkin A, Klein DF: Very high dosage vs. standard dosage fluphenazine in schizophrenia. Arch Gen Psychiatry 1975;32:1276-1281.
171. Schiele B, Mendelsohn RM, Penman AS, Schofield W: Comparison of low and high dosage procedures in chlorpromazine therapy. Psychiatr Q 1959;33:252-259.
172. Carscallen HB, Rochman H, Lovegrove TD: High dosage trifluoperazine in schizophrenia. Can Psychiatr Assoc J 1968;13:459-461.
173. Polvan N, Vagcioglu V, Itil T, Fink M: High and very high dose fluphenazine in the treatment of chronic psychosis, in Proceedings of the Sixth International Congress of Neuropsychopharmacology. Princeton, NJ, Excerpta Medica, 1968, International Congress Series No. 180, pp 495-497.
174. Simpson GM, Amin M, Kurz-Bartholini E, Watts PTS, Laska E: Problems in the evaluation of the optimal dose of a phenothiazine (butaperazine). Dis Nerv Syst 1968;29:478-484.
175. Brotman RK, Muzekari LH, Shanken PM: Butaperazine in chronic schizophrenic patients: A double-blind study. Curr Ther Res 1969;11:5-8.
176. Williams JR, Solecki RT, Puttkammer S: Effects of single, combined and non-drug treatments of chronic mental patients. Dis Nerv Syst 1969;30:696-701.
177. Clark ML, Ramsey HR, Ragland RE, Rahdal DK, Serafetinides EA, Costiloe JP: Chlorpromazine in chronic schizophrenia: Behavioral doseresponse relationships. Psychopharmacologia 1970;18:260-270.
178. Faleni RA: The use of high doses of fluphenazine in the treatment of psychotic patients. Psychosomatics 1970;11:496-499.
179. Itil T, Keskiner A, Heinemann L, Han T, Gannon P, Hsu W: Treatment of resistant schizophrenics with extreme high dosage fluphenazine hydrochloride. Psychosomatics 1970;11:456-463.
180. Itil T, Saletu B, Hsu W, Kiremitci N, Keskiner A: Clinical and quantitative EEG changes at different dosage levels of fluphenazine treatment. Acta Psychiatr Scand 1971;47:440-451.
181. DeBuck RP: Relative safety and efficacy of high and low dose administration of fluphenazine HCI to psychotic patients, in Proceedings of the Eighth International Congress of Neuropsychopharmacology. Princeton, NJ, Excerpta Medica, 1972, International Congress Series No. 184, pp 265-272.
182. Clark ML, Ramsey HR, Rahdal DK, Serafetinides EA, Wood FD, Costiloe JP: Chlorpromazine in chronic schizophrenia: The effect of age and hospitalization on behavioral dose response relationships. Arch Gen Psychiatry 1972;27:479-483.
183. Gardos G, Orzack M, Finn G, Cole JO: High and low-dose thiothixene treatment of chronic schizophrenia. Dis Nerv Syst 1974;35:53-58.
184. McClelland HA, Farquharson RG, Leyburn P, Furness JA, Schiff AA: Very high dose fluphenazine decanoate: A controlled trial in chronic schizophrenia. Arch Gen Psychiatry 1976;33:1435-1439.
185. McCreadie RG, Macdonald IM: High dosage haloperidol in chronic schizophrenia. Br J Psychiatry 1977;131:310-316.
186. Deneker SJ, Johansson R, Lundin L, Malm U: High doses of fluphenazine enanthate in schizophrenia: A controlled study. Acta Psychiatr Scand 1978;57:405-414.
187. Goldstein MJ, Rodnick EH, Evans JR, May PRA, Steinberg MR: Drug and family therapy in the aftercare of acute schizophrenics. Arch Gen Psychiatry 1978;35:1169-1177.
188. McCreadie RG, Flanagan WL, McKnight J, Jorgensen A: High dose flupenthixol decanoate in chronic schizophrenia. Br J Psychiatry 1979;135:175-179.
189. Bjørndal N, Bjerre M, Gerlach J, Kristjansen P, Magelund G, Oestrich IH, Waehrens J: High dosage haloperidol therapy in chronic schizophrenic patients: A double-blind study of clinical response, sideeffects, serum haloperidol, and serum prolactin. Psychopharmacology 1980;67:17-23.
190. Carpenter WT, Stevens JH, Rey AC, Hanlon TE, Heinrichs DW: Early intervention vs. continuous pharmacotherapy in schizophrenia. Psychopharmacol Bull 1982;18:21-23.
191. Kane JM: Antipsychotic drug side effects: Their relationship to dose. J Clin Psychiatry 1985;46:16-21.
192. Hogarty GE: Depot neuroleptics: The relevance of psychosocial factors: A United States perspective. J Clin Psychiatry 1984;45:36-42.
193. Nishikawa T, Tsuda A, Tanaka M, Hoaki Y, Koga I, Uchida Y: Prophylactic effect of neuroleptics in symptom-free schizophrenics: A comparative dose-response study of haloperidol and propericiazine. Psychopharmacology 1984;82:153-156.
194. Herz MI, Szymanski HV, Simon JC: Intermittent medication for stable schizophrenic outpatients: An alternative to maintenance medication. Am J Psychiatry 1982;139:918-922.
195. Packer R, Waud D: Pharmacological estimation of drug-receptor dissociation constants. J Pharmacol Exp Ther 1971;177:1-12.
196. Nedler JA, Mead R: A simplex method for function minimization. Comput J 1965;7:308-313.
197. Van Putten T: The clinical management of noncompliance, in Barovsky I, Budson RD (eds): The Chronic Psychiatric Patient in the Community: Principles of Treatment. Jamaica, NY, Spectrum Publications Inc, 1983, pp 383-395.
198. Hartmann W, Kind J, Meyer JE, Muller P, Steuber H: Neuroleptic drugs and the prevention of relapse in schizophrenia: A workshop report. Schizophr Bull 1980;6:536-541.
199. Gardos G, Samu I, Kallos M, Cole JO: Absence of severe tardive dyskinesia in Hungarian schizophrenic outpatients. Psychopharmacology 1980;71:29-34.
200. Doongaji DR, Jeste DV, Jape NM, Sheth AS, Apte JS, Vahia VN, Desai AB, Vahora SA, Thatte S, Vevaina T, Bharadwaj J: Tardive dyskinesia in India. J Clin Psychopharmacol 1982;2:341-344.